Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 7Completed 3Withdrawn 2Terminated 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Lymphocytic, Chronic, B-Cell 7Myelodysplastic Syndromes 6Hematologic Neoplasms 6Multiple Myeloma 5Leukemia 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Lymphoma 4Recurrence 3Melanoma 3Lymphoma, Mantle-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Biphenotypic, Acute 3Breast Neoplasms 3Stomach Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic 2Hematologic Diseases 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × fludarabine × Clear all
NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

City of Hope Medical Center

Phase 1 Withdrawn
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡